ceritinib
Selected indexed studies
- Ceritinib. (, 2006) [PMID:29999900]
- Ceritinib. (, 2012) [PMID:31643376]
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. (Lancet, 2017) [PMID:28126333]
_Worker-drafted node — pending editorial review._
Connections
ceritinib is a side effect of
Sources
- Ceritinib. (2006) pubmed
- Ceritinib. (2012) pubmed
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. (2017) pubmed
- Ceritinib: A primer for pharmacists. (2017) pubmed
- Ceritinib: first global approval. (2014) pubmed
- Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal. (2019) pubmed
- Ceritinib inhibits growth and ACTH production of PitNETs: Insights from patient-derived organoids. (2025) pubmed
- Ceritinib for the treatment of non-small cell lung cancer. (2014) pubmed
- Ceritinib-ibuprofen synergistic hepatotoxicity: Insights from real-world data and liver organoid models. (2026) pubmed
- Ceritinib for non-small cell lung cancer. (2017) pubmed